MedTrace Logo

Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma

NCT02698280 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2018-07-31

No results posted yet for this study

Summary

The purpose of this study is to determine whether bevacizumab and nimustine are effective in the treatment of recurrent high grade glioma and to explore whether there is any subgroup being sensitive to this therapeutic protocol.

Conditions

Interventions

DRUG

Bevacizumab

Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.

DRUG

Nimustine

Nimustine is administered intravenously at 90mg/m\^2 to 110mg/m\^2 every 6 weeks.

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Yu Yao, MD, PhD · Department of Neurosurgery, Huashan hospital

  • Daoying Geng, MD · Department of Radiology, Huashan hospital

  • Xiaojie Ding, MD · Department of Neurosurgery, Huashan hospital

  • Jianbo Wen, MD · Department of Radiology, Huashan hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-01-31
Completion
2018-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02698280 on ClinicalTrials.gov